Results 151 to 160 of about 120,343 (298)

Clinical characteristics and outcomes of Candida tropicalis fungemia in patients with hematologic diseases: a single-center retrospective study in China (2018-2024). [PDF]

BMC Infect Dis
Deng A, Chen S, Wu D.
europepmc   +1 more source

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

Advanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai, Shuo Wang, Xiaotong Peng, Kunpeng Wu, Mengyao Wu, Zhaoning Lu, Haoshu Zhong, Xiaohan Qian, Shuiyi Tan, Hui Yang, Tanlezi Sun, Jing Wang, Jie Zhang, Hua Jiang, Yin Tong, Tong Chen   +15 more
wiley   +1 more source

The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases. [PDF]

Stem Cell Res Ther
Deng M, Zhang X, Zhang Y.
europepmc   +1 more source

Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma

Advanced Science, EarlyView.
A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia, Xin Feng, Hongzhang Cui, Menghan Luo, Tielong Yang, Liuxing Wu, Ke Zhao, Weilong Yang, Mulin Jun Li, Dandan Huang, Jilong Yang   +19 more
wiley   +1 more source

CD19/CD22 dual‐targeting chimeric antigen receptor T‐cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B‐cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein–Barr virus viremia after transplantation

Clinical and Translational Medicine, 2023
Shijia Li, Jianrong Ge, Shiyuan Zhou, Wenjuan Zhu, Yue Han, Suning Chen, Shengli Xue, Ying Wang, Huiying Qiu, Xiaojin Wu, Depei Wu   +10 more
doaj   +1 more source

Invasive fungal infections in hematologic diseases: evidence, challenges, and clinical practice. [PDF]

Blood Res
Cho SY, Lee CE, Nho D, Lee DG.
europepmc   +1 more source

Tropomyosin 1 Promotes Platelet Adhesion and Clot Contraction Separate from Its Roles in Developmental Hematopoiesis

Advanced Science, EarlyView.
ABSTRACT Genome‐wide association studies (GWAS) link the Tropomyosin 1 (Tpm1) locus to quantitative blood trait variation, but related mechanisms are unclear. Tpm1 encodes an actin‐binding protein that regulates actin filament diversity, cell adhesion, signaling, and actomyosin contractility.
Po‐Lun Kung, Victor Tsao, Alina D Peshkova, Oscar A. Marcos‐Contreras, Kim Ha, Brian M Dulmovits, Nkemdilim Okoli, Anvi Sinha, Gennadiy Fonar, Rong Qiu, Rolf D Bates, Janelle Yeboah, Carson Shalaby, Tyler Truex, Soomin Jeong, Edna C Hardeman, Peter W Gunning, Vladimir R Muzykantov, Jacob W Myerson, Christopher S Thom   +19 more
wiley   +1 more source

Performance Evaluation of GPT-5, Grok 4, and DeepSeek R1 in Interpreting Complete Blood Count Reports for Hematologic Diseases: Retrospective Comparative Study. [PDF]

J Med Internet Res
Ye X, Qi X, Fan L, Yu Q, Zhou S, Ren C, Yang D.   +6 more
europepmc   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source

P1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.

HemaSphere, 2022
C. Li, H. Geng, X. Zong, J. Zhou, Y. Zhang, J. Li, S. Jia, D. Wu   +7 more
doaj   +1 more source